Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00353301 · ClinicalTrials.gov registry record · Phase 2

Erlotinib and Sirolimus for the Treatment of Metastatic Renal Cell Carcinoma

A Phase 2 study of Renal Cell Carcinoma, sponsored by University of Colorado, Denver.

Completed
Registry status
Phase 2
Development phase
25
Enrollment target
1
Study location

NCT00353301 is a Phase 2 study of Renal Cell Carcinoma that has completed, run by University of Colorado, Denver. The registered enrollment target is 25 participants, below the 243-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00353301, a Phase 2 study of Renal Cell Carcinoma, has completed, sponsored by University of Colorado, Denver.

COMPLETED
Registry status
Phase 2
Development phase
25 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to test the safety and efficacy of the combination of erlotinib hydrochloride (Tarceva™) and sirolimus (Rapamune™) in the treatment of patients with metastatic kidney cancer.

Conditions Studied

Renal Cell Carcinoma

Interventions

  • DRUG Sirolimus
  • DRUG Erlotinib hydrochloride

Study Locations (1)

Colorado

  • University of Colorado Hospital - Aurora

Trial Details

FieldValue
Enrollment Target 25 participants
Start Date 2006-07
Est. Completion 2012-03
Phase Phase 2

Sponsor

University of Colorado, Denver

1,283 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00353301

The ClinicalTrials.gov registry entry for NCT00353301 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 243-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (90% lower). The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Renal Cell Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Sirolimus is the first listed.

NCT00353301 reports 1 study location spanning 1 distinct geographic area - top geographies include Colorado.

Frequently Asked Questions

What is clinical trial NCT00353301 about?

NCT00353301 is a clinical study titled "Erlotinib and Sirolimus for the Treatment of Metastatic Renal Cell Carcinoma". The purpose of this study is to test the safety and efficacy of the combination of erlotinib hydrochloride (Tarceva™) and sirolimus (Rapamune™) in the treatment of patients with metastatic kidney cancer.

What is the current status of trial NCT00353301?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2006-07. Estimated completion is 2012-03.

What conditions does trial NCT00353301 study?

This clinical trial studies the following conditions: Renal Cell Carcinoma.

What interventions are being tested in trial NCT00353301?

The interventions under investigation include: Sirolimus (DRUG), Erlotinib hydrochloride (DRUG).

Who is sponsoring clinical trial NCT00353301?

This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00353301 being conducted?

This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Renal Cell Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Renal Cell Carcinoma

All registered trials for this condition

Colorado

All trials with a study site in Colorado

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.